Proximagen divests second Minster programme
This article was originally published in Scrip
Executive Summary
Proximagen is to divest its sabcomeline programme, which it acquired through its February acquisition of Minster Pharmaceuticals, to BrainCells for an upfront fee and milestone payments together worth up to $51 million, as well as a royalty on sales.